Nomogram Based on Inflammatory Factor to Predict Therapeutic Response of Thrombocytopenia in Patients with Primary Sjögren’s Syndrome

References

• Bowman SJ, Fox R, Dörner T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren’s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 2022;399(10320):161–171. doi:10.1016/s0140-6736(21)02251-0
   PubMed Web of Science ®Google Scholar
• Theander E, Mandl T. Primary Sjögren’s syndrome: diagnostic and prognostic value of salivary gland ultrasonography using a simplified scoring system. Arthritis Care Res. 2014;66(7):1102–1107. doi:10.1002/acr.22264
   Web of Science ®Google Scholar
• Manganelli P, Fietta P, Quaini F. Hematologic manifestations of primary Sjögren’s syndrome. Clin Exp Rheumatol. 2006;24(4):438–448.
   PubMed Web of Science ®Google Scholar
• Zhang S, Qu J, Wang L, et al. Activation of Toll-Like Receptor 7 Signaling Pathway in Primary Sjögren’s Syndrome-Associated Thrombocytopenia. Front Immunol. 2021;12:637659. doi:10.3389/fimmu.2021.637659
   PubMed Web of Science ®Google Scholar
• Dai F, Yang G, Rao P, et al. Clinical Characteristics of Secondary Immune Thrombocytopenia Associated With Primary Sjögren’s Syndrome. Front Med. 2020;7:138. doi:10.3389/fmed.2020.00138
   Web of Science ®Google Scholar
• Zhang W, Wang F, Wang H, Hua B, Feng X. Severe thrombocytopenia in connective tissue diseases: a single-center review of 131 cases. Clinical Rheumatology. 2018;37(12):3337–3344. doi:10.1007/s10067-018-4312-y
   PubMed Web of Science ®Google Scholar
• Luo J, Song WJ, Chen JQ, et al. Factors associated with secondary immune thrombocytopenia in patients with primary Sjögren’s syndrome: a retrospective study of 639 cases. Clin Exp Rheumatol. 2022;40(12):2245–2252. doi:10.55563/clinexprheumatol/8hgmjm
   PubMed Web of Science ®Google Scholar
• Li X, Xu B, Ma Y, et al. Clinical and laboratory profiles of primary Sjogren’s syndrome in a Chinese population: a retrospective analysis of 315 patients. Int J Rheum Dis. 2015;18(4):439–446. doi:10.1111/1756-185x.12583
   PubMed Web of Science ®Google Scholar
• Xu L, Zhang Y, Lin N. Eltrombopag improves refractory thrombocytopenia in patients with Sjögren’s syndrome. Science Progress. 2022;105(2):368504221102786. doi:10.1177/00368504221102786
   PubMed Web of Science ®Google Scholar
• Nakamura N, Tsunemine H, Sakai T, Arima N. Biomarkers for predicting response to corticosteroid therapy for immune thrombocytopenic purpura. Br J Haematol. 2023;201(4):774–782. doi:10.1111/bjh.18670
   PubMed Web of Science ®Google Scholar
• Huang X, Wang X, Yu D. Development and validation of a nomogram for renal involvement in primary Sjögren syndrome patients: a retrospective analysis. Modern Rheumatology. 2023;33(1):169–174. doi:10.1093/mr/roab123
   PubMed Web of Science ®Google Scholar
• Ye W, Chen S, Huang X, et al. Clinical features and risk factors of neurological involvement in Sjögren’s syndrome. BMC Neurosci. 2018;19(1):26. doi:10.1186/s12868-018-0427-y
   PubMedGoogle Scholar
• Xu X, Shi Y, Yang X, Zhang Y, Qin L, Cai L. Risk factors for hypertension in primary Sjögren’s syndrome patients: a nomogram was constructed. Journal of Human Hypertension. 2022;36(11):996–1002. doi:10.1038/s41371-021-00603-7
   PubMed Web of Science ®Google Scholar
• Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9–16. doi:10.1136/annrheumdis-2016-210571
   PubMed Web of Science ®Google Scholar
• Jiang B, Li T, Guo L, Shen H, Ye S, Chen S. Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: a Retrospective Study of 21 Cases. J Clin Rheumatol. 2015;21(5):244–250. doi:10.1097/rhu.0000000000000273
   PubMed Web of Science ®Google Scholar
• Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine. 2009;88(5):284–293. doi:10.1097/MD.0b013e3181b76ab5
   PubMed Web of Science ®Google Scholar
• Sellam J, Proulle V, Jüngel A, et al. Increased levels of circulating microparticles in primary Sjögren’s syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther. 2009;11(5):R156. doi:10.1186/ar2833
   PubMed Web of Science ®Google Scholar
• Koh JH, Lee J, Chung SH, Kwok SK, Park SH. Relation of Autoimmune Cytopenia to Glandular and Systemic Manifestations in Primary Sjögren Syndrome: analysis of 113 Korean Patients. J Rheumatol. 2015;42(10):1817–1824. doi:10.3899/jrheum.150058
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen S, Sun Y, et al. Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: a retrospective study. Medicine. 2016;95(50):e5565. doi:10.1097/md.0000000000005565
   PubMed Web of Science ®Google Scholar
• Wu J, Chang X, Zhang J, Liu C, Liu M, Chen W. Clinical and laboratory features of primary Sjögren’s syndrome complicated with mild to severe thrombocytopenia. Ann Transl Med. 2022;10(6):300. doi:10.21037/atm-22-162
   PubMed Web of Science ®Google Scholar
• Yıldız F, Gökmen O. Haematologic indices and disease activity index in primary Sjogren’s syndrome. International Journal of Clinical Practice. 2021;75(3):e13992. doi:10.1111/ijcp.13992
   PubMed Web of Science ®Google Scholar
• Zhao X, Gan Y, Jin Y, et al. Interleukin 17E associates with haematologic involvement and autoantibody production in primary Sjögren’s syndrome. Clin Exp Rheumatol. 2021;39(2):378–384. doi:10.55563/clinexprheumatol/gbjatf
   PubMed Web of Science ®Google Scholar
• Choung BS, Yoo WH. Successful treatment with intravenous immunoglobulin of severe thrombocytopenia complicated in primary Sjögren’s syndrome. Rheumatol Int. 2012;32(5):1353–1355. doi:10.1007/s00296-010-1395-4
   PubMed Web of Science ®Google Scholar
• Klepfish A, Friedman J, Schechter Y, Schattner A. Autoimmune neutropenia, thrombocytopenia and Coombs positivity in a patient with primary Sjögren’s syndrome. Rheumatology. 2001;40(8):948–949. doi:10.1093/rheumatology/40.8.948
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen S, Yang G, et al. ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases. J Med. 2021;8(1). doi:10.1136/lupus-2021-000523
   Google Scholar
• El Hasbani G, Chahine R, Uthman I, Taher AT. Intravenous immunoglobulin, neonatal alloimmune thrombocytopenia, and Sjogren’s syndrome: a case report. Eur J Obstet Gynecol Reprod Biol. 2021;258:476–477. doi:10.1016/j.ejogrb.2021.01.053
   PubMed Web of Science ®Google Scholar
• Harris EN, Asherson RA, Gharavi AE, Morgan SH, Derue G, Hughes GR. Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody. Br J Haematol. 1985;59(2):227–230. doi:10.1111/j.1365-2141.1985.tb02988.x
   PubMed Web of Science ®Google Scholar
• Kamimura T, Sato H, Iwamoto M, et al. Sjögren’s syndrome associated with chronic hepatitis C, severe thrombocytopenia, hypertrophic cardiomyopathy, and diabetes mellitus. Intern Med. 2005;44(6):657–661. doi:10.2169/internalmedicine.44.657
   PubMed Web of Science ®Google Scholar
• Stefanski AL, Tomiak C, Pleyer U, Dietrich T, Burmester GR, Dörner T. The Diagnosis and Treatment of Sjögren’s Syndrome. Dtsch Arztebl Int. 2017;114(20):354–361. doi:10.3238/arztebl.2017.0354
   PubMed Web of Science ®Google Scholar
• Negrini S, Emmi G, Greco M, et al. Sjögren’s syndrome: a systemic autoimmune disease. Clin Exp Med. 2022;22(1):9–25. doi:10.1007/s10238-021-00728-6
   PubMed Web of Science ®Google Scholar
• Lu C, Pi X, Xu W, et al. Clinical significance of T cell receptor repertoire in primary Sjogren’s syndrome. EBioMedicine. 2022;84:104252. doi:10.1016/j.ebiom.2022.104252
   PubMed Web of Science ®Google Scholar
• Levesque MC. Translational Mini-Review Series on B Cell-Directed Therapies: recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol. 2009;157(2):198–208. doi:10.1111/j.1365-2249.2009.03979.x
   PubMed Web of Science ®Google Scholar
• Zhou M, Yuan F. Hypocomplementemia in Primary Sjogren’s Syndrome: a Retrospective Study of 120 Treatment-Naive Chinese Patients. Int J Gen Med. 2022;15:359–366. doi:10.2147/ijgm.s346188
   PubMed Web of Science ®Google Scholar
• Lin W, Xin Z, Wang J, et al. Hypocomplementemia in primary Sjogren’s syndrome: association with serological, clinical features, and outcome. Clinical Rheumatology. 2022;41(7):2091–2102. doi:10.1007/s10067-022-06135-w
   PubMed Web of Science ®Google Scholar
• Jordán-González P, Gago-Piñero R. Characterization of a subset of patients with primary Sjögren’s syndrome initially presenting with C3 or C4 hypocomplementemia. Clin Med J. 2020;7(3):112–117. doi:10.5152/eurjrheum.2020.19132
   Google Scholar
• Campar A, Isenberg DA. Primary Sjögren’s syndrome activity and damage indices comparison. Eur J Clin Invest. 2010;40(7):636–644. doi:10.1111/j.1365-2362.2010.02303.x
   PubMed Web of Science ®Google Scholar
• Lundtoft C, Sjöwall C, Rantapää-Dahlqvist S, et al. Strong Association of Combined Genetic Deficiencies in the Classical Complement Pathway With Risk of Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome. Arthritis Rheumatol. 2022;74(11):1842–1850. doi:10.1002/art.42270
   PubMed Web of Science ®Google Scholar
• Solans-Laqué R, López-Hernandez A, Bosch-Gil JA, Palacios A, Campillo M, Vilardell-Tarres M. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren’s syndrome. Semin Arthritis Rheum. 2011;41(3):415–423. doi:10.1016/j.semarthrit.2011.04.006
   PubMed Web of Science ®Google Scholar
• Cheloff AZ, Kuter DJ, Al-Samkari H. Serum complement levels in immune thrombocytopenia: characterization and relation to clinical features. Research and Practice in Thrombosis and Haemostasis. 2020;4(5):807–812. doi:10.1002/rth2.12388
   PubMed Web of Science ®Google Scholar
• Maślińska M, Wojciechowska B, Mańczak M. Serum immunoglobulin G4 in Sjögren’s syndrome: a pilot study. Rheumatology International. 2020;40(4):555–561. doi:10.1007/s00296-020-04529-0
   PubMed Web of Science ®Google Scholar
• Pu J, Wang X, Riaz F, et al. Effectiveness and Safety of Iguratimod in Treating Primary Sjögren’s Syndrome: a Systematic Review and Meta-Analysis. Front Pharmacol. 2021;12:621208. doi:10.3389/fphar.2021.621208
   PubMed Web of Science ®Google Scholar
• Wang Y, Xie X, Zhang C, et al. Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren’s syndrome shared megakaryocyte expansion in peripheral blood. Annals of the Rheumatic Diseases. 2022;81(3):379–385. doi:10.1136/annrheumdis-2021-220066
   PubMed Web of Science ®Google Scholar
• Szyszko EA, Aqrawi LA, Jonsson R, Brokstad KA, Skarstein K. Non-proliferating plasma cells detected in the salivary glands and bone marrow of autoimmune NOD.B10.H2b mice, a model for primary Sjögren’s syndrome. Autoimmunity. 2016;49(1):41–49. doi:10.3109/08916934.2015.1079820
   PubMed Web of Science ®Google Scholar
• Tripathi AK, Mishra S, Kumar A, Yadav D, Shukla A, Yadav Y. Megakaryocyte morphology and its impact in predicting response to steroid in immune thrombocytopenia. Platelets. 2014;25(7):526–531. doi:10.3109/09537104.2013.845875
   PubMed Web of Science ®Google Scholar
• Khodadi E, Asnafi AA, Shahrabi S, Shahjahani M, Saki N. Bone marrow niche in immune thrombocytopenia: a focus on megakaryopoiesis. Ann Hematol. 2016;95(11):1765–1776. doi:10.1007/s00277-016-2703-1
   PubMed Web of Science ®Google Scholar
• Zhao L, Xu D, Qiao L, Zhang X. Bone Marrow Megakaryocytes May Predict Therapeutic Response of Severe Thrombocytopenia in Patients with Systemic Lupus Erythematosus. J Rheumatol. 2016;43(6):1038–1044. doi:10.3899/jrheum.150829
   PubMed Web of Science ®Google Scholar
• Szanto A, Szodoray P, Kiss E, Kapitany A, Szegedi G, Zeher M. Clinical, serologic, and genetic profiles of patients with associated Sjögren’s syndrome and systemic lupus erythematosus. Hum Immunol. 2006;67(11):924–930. doi:10.1016/j.humimm.2006.06.006
   PubMed Web of Science ®Google Scholar